Insmed Incorporated
Trade Insmed Incorporated 24 hours a day, five days a week on Robinhood.
Robinhood gives you the tools to revolutionize your trading experience. Use the streamlined mobile app, or access advanced charts and execute precise trades on our browser-based platform, Robinhood Legend. Risks and limitations apply.About INSM
Insmed, Inc. is a global biopharmaceutical company, which engages in the development and commercialization of therapies for patients with rare diseases. Its focuses on Brensocatib, and Treprostinil Palmitil Inhalation Powder (TPIP) pipeline.
INSM Key Statistics
Stock Snapshot
The current Insmed Incorporated(INSM) stock price is $147.60, with a market capitalization of 31.82B. The stock trades at a price-to-earnings (P/E) ratio of -23.05.
On 2026-03-27, Insmed Incorporated(INSM) stock opened at $148.45, reached a high of —, and a low of —.
The Insmed Incorporated(INSM)'s current trading volume is 0, compared to an average daily volume of 2.55M.
In the last year, Insmed Incorporated(INSM) shares hit a 52-week high of $212.75 and a 52-week low of $60.40.
In the last year, Insmed Incorporated(INSM) shares hit a 52-week high of $212.75 and a 52-week low of $60.40.
INSM News
H.C. Wainwright raised the firm’s price target on Insmed (INSM) to $245 from $230 and keeps a Buy rating on the shares. Recently announced positive ENCORE data...
Insmed CEO reveals Japan patient population exceeds US market for lung disease By William Temple Published Mar 25, 10:58AM EDT Quick Read Insmed (INSM) announ...
If you are wondering whether Insmed at US$139.14 is priced for opportunity or already reflecting a lot of expectations, the starting point is to get very clear...
Analyst ratings
95%
of 21 ratingsMore INSM News
TD Cowen raised the firm’s price target on Insmed (INSM) to $243 from $241 and keeps a Buy rating on the shares. The firm updated its model following the releas...
Wells Fargo raised the firm’s price target on Insmed (INSM) to $177 from $175 and keeps an Overweight rating on the shares. The firm thinks the Arikayce top lin...
In a report released today, Danielle Brill from Truist Financial maintained a Buy rating on Insmed, with a price target of $205.00. Claim 30% Off TipRanks Premi...
In early trading on Monday, shares of Insmed topped the list of the day's best performing components of the Nasdaq 100 index, trading up 8.4%. Year to date, Ins...
An announcement from Insmed ( (INSM) ) is now available. On March 23, 2026, Insmed reported positive topline results from its Phase 3b ENCORE study of ARIKAYCE...
Insmed (INSM) announced positive topline results from the Phase 3b ENCORE study. This study evaluated ARIKAYCE plus multidrug therapy once-daily versus placebo...
People also own
Similar Marketcap
This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.
Popular Stocks
This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset
Newly Listed
This list is generated by showing companies that recently went public.